Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Transcenta Starts Phase II Trial of Claudin18.2 Therapy for Biliary Tract Cancer

publication date: Feb 28, 2022

Transcenta, a Suzhou biopharma, has dosed the first patient in a China Phase IIa trial of its Claudin18.2 mAb in biliary tract cancer patients. The trial will test the candidate as a first-line therapy, combined with cisplatin and gemcitabine, in patients with locally advanced or metastatic disease. A rare malignancy, biliary tract cancer includes cholangiocarcinoma and gallbladder carcinoma. Most patients with these diseases are not candidates for surgical resection because they are usually diagnosed after the cancer has become metastatic. Available therapies are often ineffective. More details....

Stock Symbol: (HK: 06628)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.